Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Global Cord Blood Corporation is a diagnostics & research business based in the US. Global Cord Blood Corporation shares (CO) are listed on the NYSE and all prices are listed in US Dollars. Global Cord Blood Corporation employs 1,260 staff and has a market cap (total outstanding shares value) of USD$532.4 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$2.54 - USD$4.67 |
---|---|
50-day moving average | USD$4.1303 |
200-day moving average | USD$3.8229 |
Wall St. target price | USD$15 |
PE ratio | 14.9488 |
Dividend yield | USD$0.076 (1.68%) |
Earnings per share (TTM) | USD$0.293 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Global Cord Blood Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Global Cord Blood Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Global Cord Blood Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Global Cord Blood Corporation shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Gross profit TTM | USD$1 billion |
---|---|
Return on assets TTM | 4.95% |
Return on equity TTM | 13.12% |
Profit margin | 42.12% |
Book value | $4.094 |
Market capitalisation | USD$532.4 million |
TTM: trailing 12 months
There are currently 138,742 Global Cord Blood Corporation shares held short by investors – that's known as Global Cord Blood Corporation's "short interest". This figure is 37.9% down from 223,469 last month.
There are a few different ways that this level of interest in shorting Global Cord Blood Corporation shares can be evaluated.
Global Cord Blood Corporation's "short interest ratio" (SIR) is the quantity of Global Cord Blood Corporation shares currently shorted divided by the average quantity of Global Cord Blood Corporation shares traded daily (recently around 182555.26315789). Global Cord Blood Corporation's SIR currently stands at 0.76. In other words for every 100,000 Global Cord Blood Corporation shares traded daily on the market, roughly 760 shares are currently held short.
However Global Cord Blood Corporation's short interest can also be evaluated against the total number of Global Cord Blood Corporation shares, or, against the total number of tradable Global Cord Blood Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Global Cord Blood Corporation's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Global Cord Blood Corporation shares in existence, roughly 0 shares are currently held short) or 0.004% of the tradable shares (for every 100,000 tradable Global Cord Blood Corporation shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Global Cord Blood Corporation.
Find out more about how you can short Global Cord Blood Corporation stock.
We're not expecting Global Cord Blood Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Global Cord Blood Corporation's shares have ranged in value from as little as $2.54 up to $4.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Global Cord Blood Corporation's is 0.3607. This would suggest that Global Cord Blood Corporation's shares are less volatile than average (for this exchange).
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2020, it had three operating cord blood banks in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.